Senior Director, Global Medical Cardiovascular, Medical Product Lead

At Bristol Myers Squibb, our employees often ask, “Who are you working for?”—a question that fuels collaboration, accountability, and urgency in our work. Our purpose-driven culture inspires us to discover, develop, and deliver innovative medicines to prevail over serious diseases. We offer uniquely interesting and meaningful work, opportunities for growth, and a supportive environment that values inclusion, wellbeing, flexibility, and comprehensive benefits.

This is work that transforms the lives of patients, and the careers of those who do it.

Position Summary This is a critical role for the development and execution of BMS' Worldwide medical strategy for Milvexian within the cardiovascular portfolio. The WW Medical Product Lead (MPL) for Milvexian is a strategic leader within the Worldwide Medical organization and a key leader of the cross‑functional matrix, providing medical insight and interpretation of the evolving anticoagulation, thrombosis, atrial fibrillation, and cerebrovascular disease landscapes and disseminating emerging clinical data across the organization.

As Milvexian is being advanced through an alliance partnership, the MPL also has accountability to work collaboratively across alliance governance and joint team environments to help shape aligned strategies while appropriately representing and advancing BMS medical priorities and interests. The MPL has overall accountability to develop aligned WW medical strategies and execute core medical deliverables, including Integrated Evidence Plans, Scientific Narratives, and External Engagement and Advocacy plans as the lead of the cross‑functional Asset/Indication Medical Strategy (AIMS) team.

The Senior Director, WW MPL will have oversight over the Milvexian asset from a Worldwide Medical perspective, with primary focus on two potential indications: atrial fibrillation (AF) and secondary stroke prevention, based on the Phase 3 LIBREXIA‑AF and LIBREXIA‑STROKE trials. This role will be closely coordinated with the US Medical Lead responsibilities, ensuring clear separation of WW and US accountabilities while maintaining strategic alignment across the asset.

The successful candidate should be able to direct and navigate complex issues across a broad cross‑functional matrix to ensure optimal WW medical affairs strategy is developed and executed. This senior medical leader will report to the VP. Head of Cardiovascular Medical Affairs.

Develop and execute the Worldwide Medical Affairs strategy for Milvexian across priority indications, with initial focus on atrial fibrillation (AF) and secondary stroke prevention, ensuring alignment with the overall BMS cardiovascular disease area strategy. Serve as the core WW medical representative for Milvexian Program Teams, providing strategic medical and scientific leadership across cross‑functional global forums. Lead the cross‑functional Asset/Indication Medical Strategy (AIMS) team for Milvexian, setting strategic direction and aligning WW medical deliverables across global markets.

Define the WW medical strategy and scientific narrative for Milvexian, incorporating the factor XIa mechanism, emerging anticoagulation science, and the evolving external treatment landscape in atrial fibrillation and secondary stroke prevention. Ensure Milvexian is effectively positioned within the BMS cardiovascular disease area strategy, integrating competitive intelligence, evolving standards of care, and insight generation across thrombosis prevention settings. Provide WW medical leadership for the Milvexian asset focused on the Phase 3 LIBREXIA‑AF study in atrial fibrillation and the Phase 3 LIBREXIA‑STROKE study in secondary stroke prevention, translating…